Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M347Revenue (TTM) $M25.2Net Margin (%)-285.2Altman Z-Score-8.9
Enterprise Value $M342EPS (TTM) $-1.0Operating Margin %-244.2Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-285.2Higher ROA y-yN
Price/Book25.910-y EBITDA Growth Rate %-7.2Quick Ratio0.8Cash flow > EarningsY
Price/Sales13.75-y EBITDA Growth Rate %-10.7Current Ratio0.8Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-60.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-156.9Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M73.7ROIC % (ttm)-325.1Gross Margin Increase y-yN

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BCRXJohn Paulson 2016-03-31 Buy 0.01%$1.66 - $10.32
($4.53)
$ 4.714%New holding263,100
BCRXJoel Greenblatt 2016-03-31 Sold Out $1.66 - $10.32
($4.53)
$ 4.714%Sold Out0
BCRXJoel Greenblatt 2015-12-31 Buy $8.28 - $12.44
($9.93)
$ 4.71-53%New holding19,424
BCRXGeorge Soros 2014-06-30 Sold Out -0.01%$7.37 - $12.52
($9.68)
$ 4.71-51%Sold Out0
BCRXGeorge Soros 2014-03-31 Buy 0.01%$7.6 - $12.83
($10.56)
$ 4.71-55%New holding59,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Barnes Alane PVP, General Counsel & Corp Sec 2016-09-14Sell8,357$4.2710.3view
Babu Yarlagadda SSenior VP - Drug Discovery 2016-08-25Sell30,000$4.0616.01view
BAKER BROS. ADVISORS LP10% Owner 2016-08-16Sell4,046,590$5-5.8view
STAAB THOMAS R IISenior Vice President and CFO 2016-08-12Sell5,864$5.18-9.07view
STAAB THOMAS R IISenior Vice President and CFO 2016-08-09Sell14,577$4.436.32view
BAKER BROS. ADVISORS LP10% Owner 2016-02-05Buy45,000$6.33-25.59view
BAKER BROS. ADVISORS LP10% Owner 2016-02-04Buy207,715$6.43-26.75view
BAKER BROS. ADVISORS LP10% Owner 2016-01-28Buy88,345$6.95-32.23view
BAKER BROS. ADVISORS LP10% Owner 2016-01-22Buy106,800$7.28-35.3view
BAKER BROS. ADVISORS LP10% Owner 2016-01-20Buy344,895$7.28-35.3view

Quarterly/Annual Reports about BCRX:

News about BCRX:

Articles On GuruFocus.com
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,249 Shares Apr 06 2010 

More From Other Websites
7:33 am BioCryst Pharma closed a $23 million senior credit facility; cash runway extended to early... Sep 26 2016
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 26 2016
BioCryst Closes $23 Million Senior Credit Facility Sep 26 2016
BioCryst Closes $23 Million Senior Credit Facility Sep 26 2016
5 Stocks Under $10 That Could Make You a Lot of Money Sep 22 2016
ETF’s with exposure to BioCryst Pharmaceuticals, Inc. : September 21, 2016 Sep 21 2016
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 07 2016
BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in... Sep 07 2016
BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in... Sep 07 2016
BioCryst to Present at the Baird 2016 Global Healthcare Conference September 8 Aug 31 2016
ETF’s with exposure to BioCryst Pharmaceuticals, Inc. : August 29, 2016 Aug 29 2016
Biocryst Pharmaceuticals Inc (BCRX): Billionaire David E. Shaw’s Fund Increases Stake Aug 23 2016
BIOCRYST PHARMACEUTICALS INC Financials Aug 17 2016
Biocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 Million Shares Aug 17 2016
ETF’s with exposure to BioCryst Pharmaceuticals, Inc. : August 15, 2016 Aug 15 2016
BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12,... Aug 12 2016
BioCryst Pharma upgraded by Piper Jaffray Aug 12 2016
BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema Aug 11 2016
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 11 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)